N/A N=30 Nashville - Hypertension Management Model
Hypertension
Primary: Change in Systolic and Diastolic Blood Pressure — 21.1; 19.5 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=655 A Real-World Evidence Study to Evaluate Oral Health Related Quality of Life Using an Anti-Sensitivity Toothpaste
Dentin Sensitivity
Primary: Mean Score of DHEQ Section 1 - Impact on Everyday Life (Question [Q]1-3) at Baseline (Day 0) — 5.90; 6.17; 5.20 score on a scale
Phase 1 N=49 Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
Healthy
Primary: Absolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20 — 64; 73; 77; 84 Percent bioavailability
Phase 3 N=448 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Esophageal Carcinoma
Primary: Overall Survival (OS) — 8.28; 6.24 months
N/A N=23 SHARE-D: a Decision Tool to Help Patients Make Informed Lifestyle Choices
Health Behavior
Primary: Recruitment Rate — 45; 23 Participants
N/A N=298 Vitamin D and Screening Colonoscopy or Polyp Surveillance
Colon Cancer
Primary: Serum Vitamin D — 155; 73 Participants
Phase 2 N=64 Envarsus XR in Lung Transplant
Lung Transplant
Primary: Percentage of Patients Remaining on Envarsus XR at 1 Year — 40 Participants
Early Phase 1 N=32 Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Chronic Lymphocytic Leukemia (CLL) · Waldenstrom Macroglobulinemia (WM)
Primary: Number of Participants With Humoral Response to Vaccination 4 Weeks After the Second Vaccine Administration — 24 Participants
Phase 3 N=317 Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
Follicular Lymphoma
Primary: Best Overall Response Rate (BORR) for Low Tumor Burden Follicular Lymphoma — 80.2; 79.4 percentage of participants
Phase 1 N=15 Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants
N/A N=49 Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery
Pain
Primary: Number of Participants With a Decrease in Pain Level — 18; 16 Participants
N/A N=99 Alcohol Intervention for First Year College Students
Underage Alcohol Use
Primary: Acceptability-Number of Participants Who Found the Study Overall Favorable — 38; 0 Participants
N/A N=93,313 The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity
Alimentary Obesity
Primary: Body Weight Loss After 3, 6 & 12 Month Treatment — -9.5; -9.0; -15.0; -14.4 kg
Phase 4 N=390 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
COVID-19 · Venous Thromboembolism · Arterial Thrombosis
Primary: Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation — 4,486; 2,351 Number of wins — p=0.028
Phase 1 N=16 A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 7160; 4850 ng/mL